CATX to Unveil Full Clinical Data at ASCO 2026, Including [212Pb]VMT01 Melanoma Results

What happened

Perspective Therapeutics announced that updated data from all three clinical programs—[212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359—will be presented at the 2026 ASCO Annual Meeting in late May. The presentation includes first findings from the [212Pb]VMT01 melanoma trial, which previous filings noted as an early-stage program. For the lead neuroendocrine program VMT-α-NET, the ASCO update will provide cohort-complete data from Cohort 2 (23 patients pending) and initial Cohort 3 results, addressing the efficacy gap flagged in the DeepValue analysis. While the company touts this as a comprehensive showcase, the market has previously penalized “good-but-not-great” data, as seen after ESMO 2025. The ASCO readout is the binary event that will determine whether CATX’s 2026 rerating thesis holds or breaks.

Implication

The ASCO disclosures are the key catalyst to test whether CATX’s clinical differentiation can support a registrational pathway; without a clear efficacy step-up versus AlphaMedix benchmarks, the premium valuation embedded at current levels will dissipate amid ongoing dilution risk.

Thesis delta

The ASCO data will directly test the bull scenario’s core assumption—that higher-dose Cohort 3 delivers a meaningful efficacy step-up without new safety issues. If ORR reaches ≥45% with durable responses, the thesis shifts from “wait for evidence” to “compelling differentiated data,” potentially triggering re-rating. Conversely, flat or modest results (≤35%) would reinforce the bear case and likely push the stock toward the attractive entry of $4.50 or lower.